Skip to main content

Table 1 Clinical characteristics of patients treated with subcutaneous treprostinil referred for the pump implantation and the postimplantation parameters

From: An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil

Pt Age range [yrs.] PAH etiology Duration of sc. therapy [months] Dose sc. [ng/kg/min] Dose iv. [ng/kg/min] WHO FC before implantation WHO FC after implantation FU [months] Complications
1 42 Corrected CHD 6 38,0 40,0 II II 29 None
2 28 Corrected CHD 50 62,5 80,0 III III 24 None
3 37 Idiopathic PAH 6 20,0 30,5 III III 21 Unexpected acceleration in drug delivery
4 40 Idiopathic PAH 8 22,5 22,5 II II 19 Slight dislocation of pump without clinical implications
5 68 Connective tissue disease 8 27,0 30,0 II III 12 Died because of lung cancer, no problems with the pump
6 54 Eisenmenger 6 25,5 43,5 III II 16 None
7 25 Eisenmenger 9 41,3 42,0 III III 15 None
8 38 Idiopathic PAH 27 40,2 41,3 III III 13 Dislocation of the catheter, decrease in delivery rate
9 57 Connective tissue disease 10 33,9 35,4 II II 11 None
10 53 Idiopathic PAH 29 40,4 44,0 II II 10 None
11 30 Corrected CHD 7 17,0 40,0 III IV 4 Recurrent hematoma at implantation site, decrease in delivery rate
12 32 Connective tissue disease 2 39,0 46,0 III II 4 None
  1. PAH – pulmonary arterial hypertension, CHD – congenital heart disease, WHO FC – WHO functional class, FU – follow-up [months]
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us